Abstract: A dental restorative composition is provided that includes a polymerizable resin, a substantially translucent structural filler, a nanofiller having a mean particle size less than 100 nm, and at least one rheology-modifying additive. In one embodiment, the structural filler has a refractive index substantially similar to that of the polymerizable resin, a coarse particle fraction, and a fine particle fraction having a mean particle size greater than 0.1 ?m and smaller than the mean particle size of the coarse particle fraction. The relative ratio of the coarse particle fraction to the fine particle fraction is in the range from about 12:1 to about 2:1 by volume, the particle size distribution of each fraction is essentially monomodal, and the D(90) of the fine particle fraction is less than or equal to the D(10) of the coarse particle fraction.

Abstract: The present invention relates to novel free-radically curable dental compositions, comprising chain-like and/or cyclic and/or cage-type polysiloxanes substituted by free-radically polymerizable groups and having at least 3 silicon atoms and/or mixed forms thereof, disiloxanes substituted by free-radically polymerizable groups, optionally one, two, three or more free-radically curable dental monomers having no silicon atom, fillers, initiators and/or catalysts for free-radical polymerization, and also further customary additives, to the cured dental products formed from the dental compositions of the invention, and to the respective use thereof as dental material, especially as flowable filling composites (called “flow materials”), core buildup materials and luting cements. The invention further relates to a method for producing the dental compositions and to a process for producing a respective dental product.

Abstract: A packaged product, including: a. a package; b. a cleansing product comprising perfume; and c. a hanger made of an elastic material, wherein the product and the hanger are within the package and the hanger has a modulus at 100% strain of 30 to 700 gf/mm2 when measured in accordance with the Modulus Test.

Abstract: A personal care composition includes a structured cleansing phase and two separate benefit phases, wherein the first benefit phase containing a high viscosity benefit agent with an average particle size of about 50 ?m to about 500 ?m, wherein the second benefit phase comprises a low viscosity benefit agent with an average particle size of about 0.5 ?m to about 10 ?m.

Abstract: Described are personal care compositions comprising a polyacrylate oil gel, comprising: (a) at least one cosmetically acceptable hydrophobic ester oil, and (b) one or more polymers comprising: (i) a first polymerized unit, comprising: (1) 75% to 35% by weight, based on the weight of said polymerized unit, one or more (meth)acrylate monomers selected from at least one of C1-C4 (meth)acrylate, (meth)acrylic acid, styrene, or substituted styrene, and (2) 25% to 65% by weight, based on the weight of said polymerized unit, one or more hydrophobic monomers, including hydrophobically substituted (meth)acrylate monomers, with alkyl chain length from C6 to C22 and, (ii) a second polymerized unit, comprising: (1) 10-99% by weight, based on the weight of said polymerized unit, one or more monomers which has a Tg of more than 80° C. after polymer formation, (2) 1-10% of one or more (meth)acrylate monomers containing acid functional group, and (iii) optionally, a crosslinker.

Abstract: A hair cosmetic material includes a first agent containing an alkali agent and a second agent containing an oxidizing agent. These first agent and second agent are used in a double structure container provided with a mechanism of separating the first agent and the second agent from each other and simultaneously discharging the both agents by a propellant. In the double structure container, a space for filling the first agent and a space for filing the second agent are each independently provided in the inside of a compressed gas filling space having a propellant for pressurization filled therein. Each of the first agent and the second agent is discharged in a liquid state, and each of the first agent and the second agent has a viscosity falling within the range of from 7,000 to 30,000 mPa·s at 25° C.

Abstract: Disclosed is a water-in-silicone emulsion comprising a discontinuous water phase, a continuous silicone phase, and a silicone polyglucoside containing emulsifier, wherein the discontinuous water phase does not include a salt.

Abstract: A personal care composition includes a structured cleansing phase; a benefit phase including triglycerides, a cationic deposition polymer, and anionic microcapsules; and a carrier; and methods relating thereto.

Abstract: Use of benzyl alcohol as a defoaming agent and an antimicrobial agent in an oral care composition including a surfactant. Also described is a method of manufacturing an oral care composition including forming an oral care base composition, subsequently combining the oral care base composition with a defoaming agent and at least one surfactant to form the oral care composition; and defoaming the oral care composition. The surfactant is combined with the oral care base composition no later than the defoaming agent. The defoaming agent is benzyl alcohol.

Abstract: The disclosure relates to devices, compositions, and methods to create long lasting cosmetic contouring on a human body. Cosmetic contouring aesthetically enhances visual appearance by creating the appearance of depth to highlight certain features and/or minimize other features. Cosmetic contouring can be applied to the entire body, however, it is most frequently used on the face. In one embodiment the disclosure relates to using skin darkening compounds such as dyes or sunless tanning agents to create a long lasting cosmetic contouring effect.

Abstract: A synergistic preservative composition comprises sorbic acid or a salt thereof, benzyl alcohol, and a mixture of (i) 1,2-propanediol and/or 1,3-propanediol, and (ii), 4-butanediol and/or 1,3-butanediol. The composition is particularly suited for the preservation of cosmetics and personal care products.

Abstract: A composition including a buffered lactic acid having a pH within the range of from 3.0 to 6.5 is disclosed. The composition is a lubricant composition and has a water activity of from 0.03 to 0.60. The friction between the absorbent product and the skin/mucous membrane of the user is reduced when in contact with the skin or mucous membrane of the user. An additional advantage is that the composition has a pH in the acidic range which is close to the pH of the skin and/or mucous membrane.

Abstract: The invention relates to a process for dyeing keratin fibres, comprising the use of one or more metal catalysts and of a composition (A) comprising: —one or more oxidizing agents, and —at least one monoaminobenzene of formula (I), or an addition salt or solvate thereof in which the radicals R1 to R5 represent, independently of each other: a hydrogen atom; a halogen atom, a C1-C6 alkyl radical, a C1-C6 alkoxy radical, a carboxylic radical (—COOH), a sulfonic radical (—SO3 H); two of the adjacent radicals R1 to R5 possibly forming, with the carbon atoms that bear them, a saturated or unsaturated 5- to 7-membered ring, optionally comprising from 1 to 2 heteroatoms, preferably oxygen, the said ring being optionally fused with a saturated or unsaturated 5- to 6-membered ring; on condition that at least one of the radicals R1 to R5 represents an optionally substituted alkoxy radical and preferably at least one of the other radicals R1 to R5 is a hydrogen atom.

Abstract: The invention relates generally to new compounds of formula (I), wherein R1, R?1, R2, R?2, R3, R?3, R4 R?4, R5, R?5, R6, R7 are independently of one another and denote hydrogen, hydroxyl, C1 to C6-alkyl group or R6 and R7 form together a C5-C6 ring system, and wherein n=0, 1, 2, 3, or 4. Moreover, the invention relates to the use of one or more compounds of formula (I) in cosmetic or pharmaceutical compositions, which are preferably dermatological compositions and are preferably used topically.

Abstract: Disclosed is a composition for improving skin condition containing a vitamin mixture, and more specifically to a composition for improving skin condition containing a vitamin mixture including ten vitamins with excellent improved effect on skin condition. The composition for improving skin condition comprises a vitamin mixture of vitamin B5, vitamin B3, vitamin E, vitamin F, vitamin B9, vitamin B6, vitamin H, vitamin B12, vitamin C, and vitamin A.

Abstract: Methods of improving (i.e., changing) the skin of a patient or consumer who does not have sensitive, dry, very oily, pigmented and/or wrinkle-prone skin to slightly oily, resistant non-pigmented and tight skin.

Abstract: The present approach relates to compositions and methods for treating fingernails, toenails, hoofs, claws and the like, in mammals. More particularly, the present approach relates to compositions and methods including a prostaglandin analog active ingredient and a carrier. The compositions and methods may be used for increasing the thickness, strength, integrity, length and/or growth rate of human nails, or both, and promoting healthy nail growth and appearance, as well as relates to compositions and methods for increasing the thickness or strength of horny parts of mammals, and promoting healthy nail, claw and hoof growth.

Abstract: Methods of enhancing deposition of a high viscosity benefit agent can include manufacturing a personal care composition comprising the high viscosity benefit agent and a low viscosity benefit agent by adding the high viscosity benefit agent and the low viscosity benefit agent separately to a cleansing phase.

Abstract: There is provided an organopolysiloxane which is excellent in extensibility as well as solubility and dispersibility in water and lower alcohols. There is provided an organopolysiloxane with a poly(N-acylalkyleneimine) segment having a repeating unit represented by the following general formula (1): wherein R1 represents a hydrogen atom or an alkyl group, an aralkyl group, or an aryl group each having 1 to 22 carbon atoms, and n is 2 or 3, wherein the segment is bound to each of at least two silicon atoms of an organopolysiloxane segment as a main chain via an alkylene group containing a hetero atom, and wherein the number-average molecular weight of the segment is 800 to 1600, the mass ratio of the organopolysiloxane segment as a main chain and the poly(N-acylalkyleneimine) segment is 65/35 to 82/18, and the weight-average molecular weight of the organopolysiloxane segment as a main chain is 10,000 to 100,000.

Abstract: The present invention relates to personal care compositions containing non-ionic surfactants and fatty compounds, which have a structured composition to provide rheological properties to these compositions. The compositions can be prepared by applying a Controlled Deformation Dynamic Mixer. By using this mixer, compositions having a relatively high viscosity can be prepared, while the concentration of active compounds is relatively low.

Abstract: A personal care composition includes a surfactant, a liquid hydrophobic benefit agent, and a crystalline hydrophobic ethylene copolymer.

Abstract: Q. Hair Regrowth Spray (Q. Hair Spray) is a combination of Dried Lavender, Dried Rosemary, Chopped Ginger, Dried Sage, Evaporated Cane Juice, Soybean oil, Extra Virgin Olive Oil, and Citric Acid boiled in distilled water. The combination of these ingredients suppresses Dihydrotestoserone , reopens the hair follicles and allows the papilla to grow hair again. This treats multiple forms of Alopecia. Q. Hair Regrowth Spray (Q. Hair Spray) allows the hair to grow back from bald and thin areas on the scalp. This was created by Dr. Levy Q.

Abstract: A hard chew matrix containing antimicrobial actives, such as nanosilver, curcumin and propolis for use in dogs and other animals is disclosed.

Abstract: Methods and compositions are described for stimulating therapeutic points of a mammal subject by applying therapeutically effective amount of one or more TRP channel agonists.

Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Abstract: There is a method of treating an animal including the step of providing a live food creature configured to be consumable to an animal to be treated. The method includes applying a beneficial substance to the live food creature such that when consumed, the beneficial substance is consumed along with the live food creature. The step of applying a beneficial substance includes injecting the beneficial substance into the live food creature. The method may include the step of feeding the live food creature to the animal to be treated.

Abstract: The invention provides stable, spray-dried, particle formulations containing rapamycin, or pharmaceutically acceptable salts of rapamycin, which are useful for pulmonary administration to the respiratory tract of a patient for the treatment of disease.

Abstract: An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned.

Abstract: A method of creating a formulation for a compound includes determining a compound interactive agent comprising at least one group that interacts with the compound, creating a carrier agent by conjugating at least one compound interactive domain comprising the at least one group that interacts with the compound with at least one hydrophilic domain, and combining the compound and the carrier agent to create the formulation. Creating the carrier agent may further include conjugating the at least one compound interactive domain with at least one hydrophobic domain so that the at least one compound interactive domain is positioned between the at least one hydrophilic domain and the at least one hydrophobic domain.

Abstract: A solubilisate composed of curcumin in a quantity of less than or equal to 10% by weight, preferably less than or equal to 7.5% by weight, particularly preferably 6% by weight, and at least one emulsifier having an HLB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, wherein the average diameter of the micelles loaded with curcumin is between 5 nm and 40 nm, preferably between 6 nm and 20 nm, particularly preferably between 7 nm and 10 nm.

Abstract: A docetaxel nano-polymer micelle lyophilized preparation is disclosed including methoxypolyethylene glycol-polylactic acid block copolymer carrier material and docetaxel, the docetaxel being is encapsulated in the carrier material. A mass ratio of the docetaxel to the carrier material is 0.01-0.15. The methoxypolyethylene glycol-polylactic acid block copolymer is formed by ring opening polymerization of D,L-lactide and methoxypolyethylene glycol. A mass ratio of the methoxypolyethylene glycol to the D,L-lactide is 1:0.55-0.65 or 1:0.73-0.89 or 1:0.91-0.99. The mass ratio of the docetaxel to the carrier is further optimized by adjusting a mass ratio of polyester to polyether in the methoxypolyethylene glycol polylactide block copolymer. The encapsulation efficiency of a docetaxel micelle prepared by the block copolymer after being re-dissolved by water can be greater than 90% at 12 hours.

Abstract: A semi-automated device that provides a mechanism to produce large-scale microparticle formulations of specific sizes with no scum layer formation, and a method for using the device.

Abstract: Embodiments may include a method for reducing a solvent concentration in a plurality of microparticles. The method may involve contacting a mixture including the plurality of microparticles and the solvent with water to form an aqueous suspension. A first portion of the solvent may dissolve into the water of the aqueous suspension to reduce the solvent concentration in the plurality of microparticles from a first solvent concentration in the mixture to a second solvent concentration in the aqueous suspension. The method may also include transferring the aqueous suspension to a concentration unit that may further reduce the solvent concentration from the second solvent concentration to a third solvent concentration. The method may further include transferring a microparticle concentrate with the third solvent concentration to a washing unit to form an amalgam of washed microparticles with a fourth solvent concentration. The method may also include drying the amalgam of washed microparticles.

Abstract: Formulations capable of extended or sustained release of high levels of caffeine or analogs, derivatives and metabolites thereof have been developed The formulations contain at least two components capable of releasing the caffeine or related compound differing rates to maintain a desired plasma level.

Abstract: The invention provides species of lipid, protein, and/or cationic molecule coated active agents and compositions comprising the coated particles. The compositions can be personal care compositions such as anti-dandruff shampoo or conditioner, skin care compositions, creams, gels, toothpastes, mouth washes, and chewing gums.

Abstract: A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.

Abstract: The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating.

Abstract: Bioadhesive films suitable for topical, local, and systemic drug delivery and methods for making the same. The films may incorporate one or more polymeric layers that enable delivery of a specific, desired dosage, to a specific, desired location over a specific, desired time period.

Abstract: Provided is a patch that ensures high storage stability of donepezil or a salt thereof and allows stable transdermal administration of the donepezil or salt thereof in an amount that provides a pharmaceutical effect. The patch includes a substrate 1 and an adhesive layer 2 stacked on and integrated with one surface of the substrate 1 and containing donepezil or a salt thereof and an acrylic adhesive containing a copolymer obtained by copolymerizing monomers that each contain a (meth)acrylic acid ester of a saturated aliphatic alcohol and do not contain vinylpyrrolidone.

Abstract: A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.

Abstract: An adhesive body tape (100) configured for application to skin including a first layer (105), wherein the first layer (105) is for receiving at least one additional layer. The tape further includes a second layer (110) deposited onto the first layer (105). The second layer (110) comprises an adhesive, a first set of ingredients and a second set of ingredients having analgesic properties, and wherein the tape (100) maintains a body part of an individual (710) in proper alignment and wherein the tape (100) transdermally delivers relief of pain to an individual (710).

Abstract: The invention relates to a stable pharmaceutical composition comprising fingolimod, a pharmaceutically acceptable salt thereof or a phosphate derivative as an active ingredient and its preparation.

Abstract: A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) Paracetamol or a derivative thereof, a pharmaceutical formulation and a dosage form comprising said combination as well as a method of treating pain, e.g. chronic or acute pain, characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.

Abstract: The present invention relates to the administration of compositions comprising trans-clomiphene or an analogue or salt thereof, for inhibiting bone resorption and bone turnover in a subject. The invention is also directed to methods for increasing bone mineral density in a subject and preventing or treating a bone related disorder in a subject comprising administering to the subject an effective amount of trans-clomiphene or an analogue or salt thereof.

Abstract: The present disclosure relates in general to methods for the treatment of neurodegenerative disease, such as Huntington's Disease, using compositions comprising cysteamine or cystamine or salts or derivatives thereof.

Abstract: The present invention relates to an acetaminophen injectable aqueous solution for use in the treatment or in the prevention of pain by spinal administration, wherein said acetaminophen injectable solution is supersaturated. In certain embodiments, the acetaminophen injectable aqueous solution is administered simultaneously, separately or sequentially with a local anaesthetic by spinal administration.

Abstract: The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.

Abstract: A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. for example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient. The formulation is sufficiently hygroscopic so as to create a condition of hypertonicity when absorbed by the skin. When the formulation is applied to the skin, the vasoactive agent can be delivered to the dermis so as to contact the vasculature of a patient.

Abstract: Therapeutic methods relating to the use of GABA-AT inhibitor compounds for the treatment of hepatocellular carcinoma.

Abstract: A method of producing a compounded medication may include formulating a compounded transdermal cream that includes combining a diclofenac sodium solution and a lidocaine and prilocaine cream. The diclofenac sodium solution may be combined in an amount providing a diclofenac concentration of between approximately 0.1% and approximately 0.75% by weight of the compounded transdermal cream. The lidocaine and prilocaine cream may be combined in an amount providing an approximate equivalent concentration of each of lidocaine and prilocaine between approximately 1.5% and approximately 2.25% by weight of the compounded transdermal cream.